BSE Live
Jan 31, 16:01Prev. Close
1258.65
Open Price
1258.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 31, 16:00Prev. Close
1257.65
Open Price
1255.00
Bid Price (Qty.)
1246.20 (29)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of GlaxoSmithKline Pharmaceuticals (in Rs. Cr.) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 3,190.08 | 2,886.42 | 3,187.35 | 3,089.48 | 2,820.03 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 24.19 | |
Revenue From Operations [Net] | 3,190.08 | 2,886.42 | 3,187.35 | 3,089.48 | 2,795.84 | |
Total Operating Revenues | 3,217.51 | 2,920.48 | 3,224.68 | 3,128.53 | 2,871.69 | |
Other Income | 76.22 | 110.19 | 77.56 | 101.48 | 53.52 | |
Total Revenue | 3,293.72 | 3,030.66 | 3,302.24 | 3,230.01 | 2,925.21 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 552.47 | 452.40 | 474.38 | 682.07 | 510.27 | |
Purchase Of Stock-In Trade | 729.44 | 823.09 | 868.92 | 645.89 | 788.42 | |
Operating And Direct Expenses | 93.46 | 81.96 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 13.83 | -26.12 | -35.43 | 25.57 | -57.94 | |
Employee Benefit Expenses | 610.23 | 616.16 | 628.55 | 537.20 | 523.40 | |
Finance Costs | 1.99 | 3.53 | 6.34 | 0.55 | 0.19 | |
Depreciation And Amortisation Expenses | 68.19 | 78.60 | 82.68 | 48.59 | 37.99 | |
Other Expenses | 462.25 | 375.21 | 629.81 | 631.33 | 599.10 | |
Total Expenses | 2,531.86 | 2,404.84 | 2,655.24 | 2,571.20 | 2,401.42 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 761.87 | 625.83 | 646.99 | 658.82 | 523.79 | |
Exceptional Items | 11.58 | -172.60 | -324.49 | 4.89 | 17.80 | |
Profit/Loss Before Tax | 773.44 | 453.23 | 322.50 | 663.71 | 541.58 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 219.43 | 158.67 | 235.31 | 192.82 | 204.34 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -10.49 | 7.87 | -47.72 | 45.52 | -14.74 | |
Tax For Earlier Years | 187.94 | 0.00 | 24.86 | 0.00 | 0.00 | |
Total Tax Expenses | 396.87 | 166.54 | 212.45 | 238.35 | 189.60 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 376.58 | 286.69 | 110.05 | 425.36 | 351.99 | |
Profit/Loss From Continuing Operations | 376.58 | 286.69 | 110.05 | 425.36 | 351.99 | |
Profit/Loss For The Period | 1,690.53 | 357.57 | 110.05 | 425.36 | 351.99 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 99.05 | 31.32 | 6.50 | 25.11 | 41.56 | |
Diluted EPS (Rs.) | 99.79 | 21.11 | 6.50 | 25.11 | 41.56 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 508.22 | 677.62 | 338.81 | 296.46 | 254.11 | |
Tax On Dividend | 0.00 | 0.00 | 69.64 | 60.94 | 51.73 | |
Equity Dividend Rate (%) | 900.00 | 300.00 | 400.00 | 200.00 | 350.00 |
15.11.2022
GlaxoSmithKline Standalone September 2022 Net Sales at Rs 905.61 crore, down 8.67% Y-o-Y
11.11.2022
GlaxoSmithKline Pharma profit rises to Rs 193 crore in September quarter
11.11.2022
GlaxoSmithKline Consolidated September 2022 Net Sales at Rs 916.87 crore, down 9.21% Y-o-Y
03.10.2022
Top 10 trading ideas for next 3-4 weeks as market melts in bear hug
15.11.2022
GlaxoSmithKline Standalone September 2022 Net Sales at Rs 905.61 crore, down 8.67% Y-o-Y
11.11.2022
GlaxoSmithKline Consolidated September 2022 Net Sales at Rs 916.87 crore, down 9.21% Y-o-Y
25.07.2022
GlaxoSmithKline Consolidated June 2022 Net Sales at Rs 745.10 crore, down 5.68% Y-o-Y
25.07.2022
GlaxoSmithKline Standalone June 2022 Net Sales at Rs 729.46 crore, down 5.69% Y-o-Y